Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851193 | 1.00 | AKR1C4 (0.47) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL366568 | 0.91 | AKR1C4 (0.47) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL29705176 | 0.91 | AKR1C4 (0.47) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL24697741 | 0.88 | KEAP1 (0.45) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL2371182 | 0.86 | LCK (0.48) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL31430795 | 0.86 | SMN1; SMN2 (0.48) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL6860298 | 0.86 | SMN1; SMN2 (0.48) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL27575950 | 0.86 | CA12 (0.52) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL1713733 | 0.85 | KDM4E (0.54) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL500029 | 0.84 | SMN1; SMN2 (0.50) | AKR1C4AKR1C3AKR1C2AKR1C1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228848-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | ELI LILLY AND COMPANY | 2025-07-17 | — | — | US | claimed |
| EP-4504710-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | Eli Lilly and Company (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119343334-A | Methods of making KRAS G12C inhibitors | 伊莱利利公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2023196959-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-10-12 | — | — | WO | claimed |
| CN-122029168-A | Methods for preparing KRAS G12C inhibitors | 伊莱利利公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4696692-A1 | CRYSTAL OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| US-20250249019-A1 | METHOD OF TREATMENT INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS | LOXO ONCOLOGY, INC. | 2025-08-07 | — | — | US | disclosed |
| US-5081254-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0417669-A2 | Pyridinyl-quinolone compounds, their preparation and use | STERLING WINTHROP INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4996355-A | Novel intermediates for the production of 2,4,5-trifluorobenzoyl fluoride | MALLINCKRODT, INC. (US) | 1991-02-26 | — | — | US | disclosed |
| WO-1990012780-A1 | INTERMEDIATES FOR THE PRODUCTION OF 2,4,5-TRIFLUORBENZOYL FLUORIDE | MALLINCKRODT, INC. (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4929613-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| EP-0309789-A1 | 4-Oxo-3-quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0306764-A2 | 4-Quinolone-3-carboxylic-acid derivatives and their use as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | AKR1C4 575/4885AKR1C3 638/4885AKR1C2 584/4885 |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | AKR1C4 2690/4885AKR1C3 1551/4885AKR1C2 2056/4885 |
| US-20250228848-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | KRAS, NRAS, HRAS | AKR1C4 918/4885AKR1C3 670/4885AKR1C2 550/4885 |
| US-20250249019-A1 | METHOD OF TREATMENT INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS | KRAS, AURKC, NRAS | AKR1C4 1309/4885AKR1C3 1212/4885AKR1C2 901/4885 |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | AKR1C4 283/4885AKR1C3 165/4885AKR1C2 343/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | AKR1C4 2439/4885AKR1C3 2097/4885AKR1C2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.